{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:08Z","timestamp":1790710148628,"version":"4.1.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02005-0","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:25:53Z","timestamp":1772198753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting epigenetic networks to overcome cisplatin resistance in ovarian cancer: from mechanisms to clinical translation"],"prefix":"10.1186","volume":"19","author":[{"given":"Maoyan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaya","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaochu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2005_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA: A cancer. J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"J Clin"},{"key":"2005_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7150\/jca.49406","volume":"12","author":"V Gogineni","year":"2021","unstructured":"Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, et al. Current ovarian cancer maintenance strategies and promising new developments. J Cancer. 2021;12:38\u201353. https:\/\/doi.org\/10.7150\/jca.49406.","journal-title":"J Cancer"},{"key":"2005_CR3","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114205.","journal-title":"Eur J Med Chem"},{"key":"2005_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.23.01771","volume":"42","author":"J St Laurent","year":"2024","unstructured":"St Laurent J, Liu JF. Treatment approaches for Platinum-Resistant ovarian cancer. J Clin Oncol. 2024;42:127\u201333. https:\/\/doi.org\/10.1200\/JCO.23.01771.","journal-title":"J Clin Oncol"},{"key":"2005_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis A, Tinker AV, Friedlander M. Platinum resistant ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2014.02.038.","journal-title":"Gynecol Oncol"},{"key":"2005_CR6","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. https:\/\/doi.org\/10.1038\/nrdp.2016.61.","journal-title":"Nat Rev Dis Primers"},{"key":"2005_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1124\/pr.111.005637","volume":"64","author":"D-W Shen","year":"2012","unstructured":"Shen D-W, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64:706\u201321. https:\/\/doi.org\/10.1124\/pr.111.005637.","journal-title":"Pharmacol Rev"},{"key":"2005_CR8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/ijms25021130","volume":"25","author":"T Lumpp","year":"2024","unstructured":"Lumpp T, St\u00f6\u00dfer S, Fischer F, Hartwig A, K\u00f6berle B. Role of epigenetics for the efficacy of cisplatin. Int J Mol Sci. 2024;25:1130. https:\/\/doi.org\/10.3390\/ijms25021130.","journal-title":"Int J Mol Sci"},{"key":"2005_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41576-021-00438-5","volume":"23","author":"MH Fitz-James","year":"2022","unstructured":"Fitz-James MH, Cavalli G. Molecular mechanisms of transgenerational epigenetic inheritance. Nat Rev Genet. 2022;23:325\u201341. https:\/\/doi.org\/10.1038\/s41576-021-00438-5.","journal-title":"Nat Rev Genet"},{"key":"2005_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ije\/dyr185","volume":"41","author":"E Jablonka","year":"2012","unstructured":"Jablonka E, Lamm E, Commentary. The epigenotype\u2013a dynamic network view of development. Int J Epidemiol. 2012;41:16\u201320. https:\/\/doi.org\/10.1093\/ije\/dyr185.","journal-title":"Int J Epidemiol"},{"key":"2005_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/ije\/dyr186","volume":"41","author":"SF Gilbert","year":"2012","unstructured":"Gilbert SF, Commentary. The epigenotype by C.H. Waddington. Int J Epidemiol. 2012;41:20\u20133. https:\/\/doi.org\/10.1093\/ije\/dyr186.","journal-title":"Int J Epidemiol"},{"key":"2005_CR12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41598-017-01624-4","volume":"7","author":"RJ Lund","year":"2017","unstructured":"Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, Moulder R, et al. DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer. Sci Rep. 2017;7:1469. https:\/\/doi.org\/10.1038\/s41598-017-01624-4.","journal-title":"Sci Rep"},{"key":"2005_CR13","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/biom12101365","volume":"12","author":"Y Lugones","year":"2022","unstructured":"Lugones Y, Loren P, Salazar LA. Cisplatin resistance: genetic and epigenetic factors involved. Biomolecules. 2022;12:1365. https:\/\/doi.org\/10.3390\/biom12101365.","journal-title":"Biomolecules"},{"key":"2005_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23\u201338. https:\/\/doi.org\/10.1038\/npp.2012.112.","journal-title":"Neuropsychopharmacology"},{"key":"2005_CR15","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.molcel.2022.02.033","volume":"82","author":"J Xiong","year":"2022","unstructured":"Xiong J, He J, Zhu J, Pan J, Liao W, Ye H, et al. Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82:1660\u2013e167710. https:\/\/doi.org\/10.1016\/j.molcel.2022.02.033.","journal-title":"Mol Cell"},{"key":"2005_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-024-02041-8","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Jin H, Li Q, Shi L, Mao Y, Zhao L. The role of RNA methylation in tumor immunity and its potential in immunotherapy. Mol Cancer. 2024;23:130. https:\/\/doi.org\/10.1186\/s12943-024-02041-8.","journal-title":"Mol Cancer"},{"key":"2005_CR17","doi-asserted-by":"publisher","first-page":"831099","DOI":"10.3389\/fphar.2022.831099","volume":"13","author":"P Loren","year":"2022","unstructured":"Loren P, Saavedra N, Saavedra K, De Godoy Torso N, Visacri MB, Moriel P, et al. Contribution of MicroRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review. Front Pharmacol. 2022;13:831099. https:\/\/doi.org\/10.3389\/fphar.2022.831099.","journal-title":"Front Pharmacol"},{"key":"2005_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12943-018-0855-4","volume":"17","author":"Q Yang","year":"2018","unstructured":"Yang Q, Yang Y, Zhou N, Tang K, Lau WB, Lau B, et al. Epigenetics in ovarian cancer: premise, properties, and perspectives. Mol Cancer. 2018;17:109. https:\/\/doi.org\/10.1186\/s12943-018-0855-4.","journal-title":"Mol Cancer"},{"key":"2005_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13148-021-01130-5","volume":"13","author":"DW Chan","year":"2021","unstructured":"Chan DW, Lam W-Y, Chen F, Yung MMH, Chan Y-S, Chan W-S, et al. Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clin Epigenetics. 2021;13:142. https:\/\/doi.org\/10.1186\/s13148-021-01130-5.","journal-title":"Clin Epigenetics"},{"key":"2005_CR20","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1038\/sj.onc.1210300","volume":"26","author":"J Staub","year":"2007","unstructured":"Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, et al. Epigenetic Silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene. 2007;26:4969\u201378. https:\/\/doi.org\/10.1038\/sj.onc.1210300.","journal-title":"Oncogene"},{"key":"2005_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ijc.25083","volume":"127","author":"H-Y Su","year":"2010","unstructured":"Su H-Y, Lai H-C, Lin Y-W, Liu C-Y, Chen C-K, Chou Y-C, et al. Epigenetic Silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 2010;127:555\u201367. https:\/\/doi.org\/10.1002\/ijc.25083.","journal-title":"Int J Cancer"},{"key":"2005_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/labinvest.2009.138","volume":"90","author":"J-L Chou","year":"2010","unstructured":"Chou J-L, Su H-Y, Chen L-Y, Liao Y-P, Hartman-Frey C, Lai Y-H, et al. Promoter hypermethylation of FBXO32, a novel TGF-beta\/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 2010;90:414\u201325. https:\/\/doi.org\/10.1038\/labinvest.2009.138.","journal-title":"Lab Invest"},{"key":"2005_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-016-0361-5","volume":"8","author":"T Tomar","year":"2016","unstructured":"Tomar T, de Jong S, Alkema NG, Hoekman RL, Meersma GJ, Klip HG, et al. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Med. 2016;8:107. https:\/\/doi.org\/10.1186\/s13073-016-0361-5.","journal-title":"Genome Med"},{"key":"2005_CR24","doi-asserted-by":"publisher","first-page":"659254","DOI":"10.3389\/fonc.2021.659254","volume":"11","author":"X-F Li","year":"2021","unstructured":"Li X-F, Sun H-Y, Hua T, Zhang H-B, Tian Y-J, Li Y, et al. Promoter methylation of the MGRN1 gene predicts prognosis and response to chemotherapy of High-Grade serous ovarian cancer patients. Front Oncol. 2021;11:659254. https:\/\/doi.org\/10.3389\/fonc.2021.659254.","journal-title":"Front Oncol"},{"key":"2005_CR25","doi-asserted-by":"publisher","first-page":"101556","DOI":"10.1016\/j.jbc.2021.101556","volume":"298","author":"J Monga","year":"2022","unstructured":"Monga J, Adrianto I, Rogers C, Gadgeel S, Chitale D, Alumkal JJ, et al. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. J Biol Chem. 2022;298:101556. https:\/\/doi.org\/10.1016\/j.jbc.2021.101556.","journal-title":"J Biol Chem"},{"key":"2005_CR26","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/ijc.30860","volume":"141","author":"D Kritsch","year":"2017","unstructured":"Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, Gajda M, et al. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. Int J Cancer. 2017;141:1600\u201314. https:\/\/doi.org\/10.1002\/ijc.30860.","journal-title":"Int J Cancer"},{"key":"2005_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13148-021-01149-8","volume":"13","author":"JA Soto","year":"2021","unstructured":"Soto JA, Rodr\u00edguez-Antol\u00edn C, Vera O, Pern\u00eda O, Esteban-Rodr\u00edguez I, Dolores Diestro M, et al. Transcriptional epigenetic regulation of Fkbp1\/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer. Clin Epigenetics. 2021;13:167. https:\/\/doi.org\/10.1186\/s13148-021-01149-8.","journal-title":"Clin Epigenetics"},{"key":"2005_CR28","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-15-1669","volume":"22","author":"NA Bonito","year":"2016","unstructured":"Bonito NA, Borley J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Brown R. Epigenetic regulation of the homeobox gene MSX1 associates with Platinum-Resistant disease in High-Grade serous epithelial ovarian cancer. Clin Cancer Res. 2016;22:3097\u2013104. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1669.","journal-title":"Clin Cancer Res"},{"key":"2005_CR29","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ijc.24797","volume":"126","author":"PS Lee","year":"2010","unstructured":"Lee PS, Teaberry VS, Bland AE, Huang Z, Whitaker RS, Baba T, et al. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer. 2010;126:1378\u201389. https:\/\/doi.org\/10.1002\/ijc.24797.","journal-title":"Int J Cancer"},{"key":"2005_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ygyno.2016.06.017","volume":"142","author":"M de Leon","year":"2016","unstructured":"de Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, et al. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer. Gynecol Oncol. 2016;142:539\u201347. https:\/\/doi.org\/10.1016\/j.ygyno.2016.06.017.","journal-title":"Gynecol Oncol"},{"key":"2005_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13048-023-01332-w","volume":"17","author":"HB Manzoor","year":"2024","unstructured":"Manzoor HB, Asare-Werehene M, Pereira SD, Satyamoorthy K, Tsang BK. The regulation of plasma Gelsolin by DNA methylation in ovarian cancer chemo-resistance. J Ovarian Res. 2024;17:15. https:\/\/doi.org\/10.1186\/s13048-023-01332-w.","journal-title":"J Ovarian Res"},{"key":"2005_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41587-023-01909-2","volume":"42","author":"EB Fabyanic","year":"2024","unstructured":"Fabyanic EB, Hu P, Qiu Q, Berr\u00edos KN, Connolly DR, Wang T, et al. Joint single-cell profiling resolves 5mC and 5hmC and reveals their distinct gene regulatory effects. Nat Biotechnol. 2024;42:960\u201374. https:\/\/doi.org\/10.1038\/s41587-023-01909-2.","journal-title":"Nat Biotechnol"},{"key":"2005_CR33","doi-asserted-by":"publisher","first-page":"956604","DOI":"10.3389\/fcell.2022.956604","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Miu K-K, Chan S-W, Ou F, Wai-Nok Law P, Chan W-Y. Genome-wide 5-hydroxymethylcytosine (5hmC) reassigned in Pten-depleted mESCs along neural differentiation. Front Cell Dev Biol. 2022;10:956604. https:\/\/doi.org\/10.3389\/fcell.2022.956604.","journal-title":"Front Cell Dev Biol"},{"key":"2005_CR34","doi-asserted-by":"publisher","first-page":"eaba8091","DOI":"10.1126\/scisignal.aba8091","volume":"13","author":"SS Kharat","year":"2020","unstructured":"Kharat SS, Ding X, Swaminathan D, Suresh A, Singh M, Sengodan SK, et al. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability. Sci Signal. 2020;13:eaba8091. https:\/\/doi.org\/10.1126\/scisignal.aba8091.","journal-title":"Sci Signal"},{"key":"2005_CR35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/abbs\/gmt113","volume":"45","author":"X Zhang","year":"2013","unstructured":"Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 2013;45:995\u20131001. https:\/\/doi.org\/10.1093\/abbs\/gmt113.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"2005_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/bjc.2016.379","volume":"116","author":"X Li","year":"2017","unstructured":"Li X, Chen W, Zeng W, Wan C, Duan S, Jiang S. microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. Br J Cancer. 2017;116:66\u201376. https:\/\/doi.org\/10.1038\/bjc.2016.379.","journal-title":"Br J Cancer"},{"key":"2005_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3892\/ijo.2017.4023","volume":"51","author":"X Li","year":"2017","unstructured":"Li X, Jin Y, Mu Z, Chen W, Jiang S. MicroRNA\u2013146a\u20135p enhances cisplatin\u2013induced apoptosis in ovarian cancer cells by targeting multiple anti\u2013apoptotic genes. Int J Oncol. 2017;51:327\u201335. https:\/\/doi.org\/10.3892\/ijo.2017.4023.","journal-title":"Int J Oncol"},{"key":"2005_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2019.01.009","volume":"161","author":"X Li","year":"2019","unstructured":"Li X, Chen W, Jin Y, Xue R, Su J, Mu Z, et al. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 2019;161:98\u2013112. https:\/\/doi.org\/10.1016\/j.bcp.2019.01.009.","journal-title":"Biochem Pharmacol"},{"key":"2005_CR39","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1002\/cam4.1682","volume":"7","author":"R Liu","year":"2018","unstructured":"Liu R, Guo H, Lu S. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med. 2018;7:4598\u2013609. https:\/\/doi.org\/10.1002\/cam4.1682.","journal-title":"Cancer Med"},{"key":"2005_CR40","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/15384101.2019.1704537","volume":"19","author":"Z Hu","year":"2020","unstructured":"Hu Z, Cai M, Zhang Y, Tao L, Guo R. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1\/ATG14 pathway. Cell Cycle. 2020;19:193\u2013206. https:\/\/doi.org\/10.1080\/15384101.2019.1704537.","journal-title":"Cell Cycle"},{"key":"2005_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/15548627.2015.1009781","volume":"11","author":"J He","year":"2015","unstructured":"He J, Yu J-J, Xu Q, Wang L, Zheng JZ, Liu L-Z, et al. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015;11:373\u201384. https:\/\/doi.org\/10.1080\/15548627.2015.1009781.","journal-title":"Autophagy"},{"key":"2005_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12935-021-02412-x","volume":"22","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Wang C, Ding J, Chen Y, Sun Y, Cheng Z. miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy. Cancer Cell Int. 2022;22:15. https:\/\/doi.org\/10.1186\/s12935-021-02412-x.","journal-title":"Cancer Cell Int"},{"key":"2005_CR43","doi-asserted-by":"publisher","first-page":"6662486","DOI":"10.1155\/2021\/6662486","volume":"2021","author":"X Kou","year":"2021","unstructured":"Kou X, Ding H, Li L, Chao H. Hsa-miR-105-1 regulates Cisplatin-Resistance in ovarian carcinoma cells by targeting ANXA9. Anal Cell Pathol (Amst). 2021;2021:6662486. https:\/\/doi.org\/10.1155\/2021\/6662486.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"2005_CR44","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.7150\/thno.20112","volume":"7","author":"O Vera","year":"2017","unstructured":"Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, et al. DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics. 2017;7:4118\u201334. https:\/\/doi.org\/10.7150\/thno.20112.","journal-title":"Theranostics"},{"key":"2005_CR45","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/j.1742-4658.2012.08589.x","volume":"279","author":"W Cheng","year":"2012","unstructured":"Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279:2047\u201359. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08589.x.","journal-title":"FEBS J"},{"key":"2005_CR46","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41419-018-1093-9","volume":"9","author":"M Yan","year":"2018","unstructured":"Yan M, Yang X, Shen R, Wu C, Wang H, Ye Q, et al. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer. Cell Death Dis. 2018;9:1123. https:\/\/doi.org\/10.1038\/s41419-018-1093-9.","journal-title":"Cell Death Dis"},{"key":"2005_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2014.07.026","volume":"353","author":"X-P Chen","year":"2014","unstructured":"Chen X-P, Chen Y-G, Lan J-Y, Shen Z-J. MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Lett. 2014;353:201\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2014.07.026.","journal-title":"Cancer Lett"},{"key":"2005_CR48","doi-asserted-by":"publisher","first-page":"602670","DOI":"10.3389\/fonc.2020.602670","volume":"10","author":"BI Qui\u00f1ones-D\u00edaz","year":"2020","unstructured":"Qui\u00f1ones-D\u00edaz BI, Reyes-Gonz\u00e1lez JM, S\u00e1nchez-Guzm\u00e1n V, Conde-Del Moral I, Valiyeva F, Santiago-S\u00e1nchez GS, et al. MicroRNA-18a-5p suppresses tumor growth via targeting matrix Metalloproteinase-3 in Cisplatin-Resistant ovarian cancer. Front Oncol. 2020;10:602670. https:\/\/doi.org\/10.3389\/fonc.2020.602670.","journal-title":"Front Oncol"},{"key":"2005_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2014.12.042","volume":"137","author":"RC Pink","year":"2015","unstructured":"Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DRF. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137:143\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2014.12.042.","journal-title":"Gynecol Oncol"},{"key":"2005_CR50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ygyno.2014.01.034","volume":"132","author":"JK Chan","year":"2014","unstructured":"Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C, et al. The Inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol. 2014;132:739\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.034.","journal-title":"Gynecol Oncol"},{"key":"2005_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2016.08.005","volume":"310","author":"N Arrighetti","year":"2016","unstructured":"Arrighetti N, Cossa G, De Cecco L, Stucchi S, Carenini N, Corna E, et al. PKC-alpha modulation by miR-483-3p in platinum-resistant ovarian carcinoma cells. Toxicol Appl Pharmacol. 2016;310:9\u201319. https:\/\/doi.org\/10.1016\/j.taap.2016.08.005.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2005_CR52","doi-asserted-by":"publisher","first-page":"113729","DOI":"10.1016\/j.bcp.2019.113729","volume":"172","author":"FE Marquard","year":"2020","unstructured":"Marquard FE, J\u00fccker M. PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 2020;172:113729. https:\/\/doi.org\/10.1016\/j.bcp.2019.113729.","journal-title":"Biochem Pharmacol"},{"key":"2005_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41388-023-02875-4","volume":"43","author":"KA Miller","year":"2024","unstructured":"Miller KA, Degan S, Wang Y, Cohen J, Ku SY, Goodrich DW, et al. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. Oncogene. 2024;43:22\u201334. https:\/\/doi.org\/10.1038\/s41388-023-02875-4.","journal-title":"Oncogene"},{"key":"2005_CR54","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.febslet.2012.03.006","volume":"586","author":"X Fu","year":"2012","unstructured":"Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN\/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012;586:1279\u201386. https:\/\/doi.org\/10.1016\/j.febslet.2012.03.006.","journal-title":"FEBS Lett"},{"key":"2005_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/0008-5472.CAN-07-2488","volume":"68","author":"H Yang","year":"2008","unstructured":"Yang H, Kong W, He L, Zhao J-J, O\u2019Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425\u201333. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2488.","journal-title":"Cancer Res"},{"key":"2005_CR56","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fgene.2018.00555","volume":"9","author":"X Shi","year":"2018","unstructured":"Shi X, Xiao L, Mao X, He J, Ding Y, Huang J, et al. miR-205-5p mediated downregulation of PTEN contributes to cisplatin resistance in C13K human ovarian cancer cells. Front Genet. 2018;9:555. https:\/\/doi.org\/10.3389\/fgene.2018.00555.","journal-title":"Front Genet"},{"key":"2005_CR57","doi-asserted-by":"publisher","first-page":"614035","DOI":"10.3389\/fonc.2021.614035","volume":"11","author":"L Dou","year":"2021","unstructured":"Dou L, Zhang Y. miR-4461 regulates the proliferation and metastasis of ovarian cancer cells and cisplatin resistance. Front Oncol. 2021;11:614035. https:\/\/doi.org\/10.3389\/fonc.2021.614035.","journal-title":"Front Oncol"},{"key":"2005_CR58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13048-021-00939-1","volume":"15","author":"L Zhong","year":"2022","unstructured":"Zhong L, Liu X, Wang L, Liu Y, Zhang D, Zhao Y. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma. J Ovarian Res. 2022;15:7. https:\/\/doi.org\/10.1186\/s13048-021-00939-1.","journal-title":"J Ovarian Res"},{"key":"2005_CR59","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3892\/ijo.2019.4731","volume":"54","author":"Y-N Chen","year":"2019","unstructured":"Chen Y-N, Ren C-C, Yang L, Nai M-M, Xu Y-M, Zhang F, et al. MicroRNA let\u20137d\u20135p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. Int J Oncol. 2019;54:1771\u201384. https:\/\/doi.org\/10.3892\/ijo.2019.4731.","journal-title":"Int J Oncol"},{"key":"2005_CR60","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12967-022-03422-7","volume":"20","author":"X Wang","year":"2022","unstructured":"Wang X, Jiang L, Liu Q. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance. J Transl Med. 2022;20:258. https:\/\/doi.org\/10.1186\/s12967-022-03422-7.","journal-title":"J Transl Med"},{"key":"2005_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-015-0464-4","volume":"14","author":"MTM van Jaarsveld","year":"2015","unstructured":"van Jaarsveld MTM, van Kuijk PF, Boersma AWM, Helleman J, van IJcken WF, Mathijssen RHJ, et al. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer. 2015;14:196. https:\/\/doi.org\/10.1186\/s12943-015-0464-4.","journal-title":"Mol Cancer"},{"key":"2005_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1089\/dna.2017.3953","volume":"37","author":"M Lin","year":"2018","unstructured":"Lin M, Xia B, Qin L, Chen H, Lou G. S100A7 regulates ovarian cancer cell metastasis and chemoresistance through MAPK signaling and is targeted by miR-330-5p. DNA Cell Biol. 2018;37:491\u2013500. https:\/\/doi.org\/10.1089\/dna.2017.3953.","journal-title":"DNA Cell Biol"},{"key":"2005_CR63","first-page":"2124","volume":"11","author":"T Li","year":"2021","unstructured":"Li T, Lin L, Liu Q, Gao W, Chen L, Sha C, et al. Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer. Am J Cancer Res. 2021;11:2124\u201341.","journal-title":"Am J Cancer Res"},{"key":"2005_CR64","doi-asserted-by":"publisher","first-page":"15300","DOI":"10.3390\/ijms232315300","volume":"23","author":"X Huang","year":"2022","unstructured":"Huang X, Yan Y, Gui A, Zhu S, Qiu S, Chen F, et al. A regulatory loop involving miR-200c and NF-\u03baB modulates Mortalin expression and increases cisplatin sensitivity in an ovarian cancer cell line model. Int J Mol Sci. 2022;23:15300. https:\/\/doi.org\/10.3390\/ijms232315300.","journal-title":"Int J Mol Sci"},{"key":"2005_CR65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11010-021-04271-6","volume":"477","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yan C, Qi J, Liu C, Yu J, Wang H. miR-874-3p mitigates cisplatin resistance through modulating NF-\u03baB\/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells. Mol Cell Biochem. 2022;477:307\u201317. https:\/\/doi.org\/10.1007\/s11010-021-04271-6.","journal-title":"Mol Cell Biochem"},{"key":"2005_CR66","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1038\/onc.2012.433","volume":"32","author":"MTM van Jaarsveld","year":"2013","unstructured":"van Jaarsveld MTM, Helleman J, Boersma AWM, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013;32:4284\u201393. https:\/\/doi.org\/10.1038\/onc.2012.433.","journal-title":"Oncogene"},{"key":"2005_CR67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41417-020-0195-6","volume":"28","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Lu L, Zhang L, Dong M. Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt\/\u03b2-catenin signaling pathway. Cancer Gene Ther. 2021;28:785\u201398. https:\/\/doi.org\/10.1038\/s41417-020-0195-6.","journal-title":"Cancer Gene Ther"},{"key":"2005_CR68","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/1078-0432.CCR-18-2554","volume":"25","author":"G Wu","year":"2019","unstructured":"Wu G, Cao L, Zhu J, Tan Z, Tang M, Li Z, et al. Loss of RBMS3 confers platinum resistance in epithelial ovarian cancer via activation of miR-126-5p\/\u03b2-catenin\/CBP signaling. Clin Cancer Res. 2019;25:1022\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2554.","journal-title":"Clin Cancer Res"},{"key":"2005_CR69","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.tranon.2020.100987","volume":"14","author":"Y Sun","year":"2021","unstructured":"Sun Y, Wu J, Dong X, Zhang J, Meng C, Liu G. MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2\/\u03b2-catenin in serous ovarian cancers. Transl Oncol. 2021;14:100987. https:\/\/doi.org\/10.1016\/j.tranon.2020.100987.","journal-title":"Transl Oncol"},{"key":"2005_CR70","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41417-022-00574-y","volume":"30","author":"Z Song","year":"2023","unstructured":"Song Z, Liao C, Yao L, Xu X, Shen X, Tian S, et al. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt\/\u03b2-catenin signaling and autophagy via targeting HMGA2. Cancer Gene Ther. 2023;30:596\u2013607. https:\/\/doi.org\/10.1038\/s41417-022-00574-y.","journal-title":"Cancer Gene Ther"},{"key":"2005_CR71","doi-asserted-by":"publisher","first-page":"BSR20180547","DOI":"10.1042\/BSR20180547","volume":"38","author":"P Jin","year":"2018","unstructured":"Jin P, Liu Y, Wang R. STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance. Biosci Rep. 2018;38:BSR20180547. https:\/\/doi.org\/10.1042\/BSR20180547.","journal-title":"Biosci Rep"},{"key":"2005_CR72","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s41388-020-01595-3","volume":"40","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Yokoi A, Sugiyama M, Oda S, Kitami K, Tamauchi S, et al. Expression of the chrXq27.3 MiRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance. Oncogene. 2021;40:1255\u201368. https:\/\/doi.org\/10.1038\/s41388-020-01595-3.","journal-title":"Oncogene"},{"key":"2005_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","volume":"106","author":"L Amable","year":"2016","unstructured":"Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27\u201336. https:\/\/doi.org\/10.1016\/j.phrs.2016.01.001.","journal-title":"Pharmacol Res"},{"key":"2005_CR74","doi-asserted-by":"publisher","first-page":"17476","DOI":"10.1038\/s41598-023-44548-y","volume":"13","author":"A Marjamaa","year":"2023","unstructured":"Marjamaa A, Gibbs B, Kotrba C, Masamha CP. The role and impact of alternative polyadenylation and MiRNA regulation on the expression of the multidrug resistance-associated protein 1 (MRP-1\/ABCC1) in epithelial ovarian cancer. Sci Rep. 2023;13:17476. https:\/\/doi.org\/10.1038\/s41598-023-44548-y.","journal-title":"Sci Rep"},{"key":"2005_CR75","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1038\/s41598-018-25930-7","volume":"8","author":"C Risnayanti","year":"2018","unstructured":"Risnayanti C, Jang Y-S, Lee J, Ahn HJ. PLGA nanoparticles co-delivering MDR1 and BCL2 SiRNA for overcoming resistance of Paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Sci Rep. 2018;8:7498. https:\/\/doi.org\/10.1038\/s41598-018-25930-7.","journal-title":"Sci Rep"},{"key":"2005_CR76","doi-asserted-by":"publisher","first-page":"e2300175","DOI":"10.1002\/advs.202300175","volume":"10","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Liang G, Guo B, Wang W, Yang C, Chen D, et al. Polyphotosensitizer-Based nanoparticles with Michael addition acceptors inhibiting GST activity and cisplatin deactivation for enhanced chemotherapy and photodynamic immunotherapy. Adv Sci (Weinh). 2023;10:e2300175. https:\/\/doi.org\/10.1002\/advs.202300175.","journal-title":"Adv Sci (Weinh)"},{"key":"2005_CR77","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13048-015-0207-6","volume":"8","author":"K-X Sun","year":"2015","unstructured":"Sun K-X, Jiao J-W, Chen S, Liu B-L, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to Paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res. 2015;8:80. https:\/\/doi.org\/10.1186\/s13048-015-0207-6.","journal-title":"J Ovarian Res"},{"key":"2005_CR78","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.2147\/DDDT.S87526","volume":"9","author":"S Chen","year":"2015","unstructured":"Chen S, Jiao J-W, Sun K-X, Zong Z-H, Zhao Y. MicroRNA-133b targets glutathione S-transferase \u03c0 expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Des Devel Ther. 2015;9:5225\u201335. https:\/\/doi.org\/10.2147\/DDDT.S87526.","journal-title":"Drug Des Devel Ther"},{"key":"2005_CR79","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00438-018-1447-0","volume":"293","author":"S Xiao","year":"2018","unstructured":"Xiao S, Zhang M, Liu C, Wang D. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer. Mol Genet Genomics. 2018;293:1159\u201367. https:\/\/doi.org\/10.1007\/s00438-018-1447-0.","journal-title":"Mol Genet Genomics"},{"key":"2005_CR80","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/IGC.0000000000000252","volume":"24","author":"B Li","year":"2014","unstructured":"Li B, Chen H, Wu N, Zhang W-J, Shang L-X. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance. Int J Gynecol Cancer. 2014;24:1381\u20138. https:\/\/doi.org\/10.1097\/IGC.0000000000000252.","journal-title":"Int J Gynecol Cancer"},{"key":"2005_CR81","doi-asserted-by":"publisher","first-page":"e0128886","DOI":"10.1371\/journal.pone.0128886","volume":"10","author":"N Li","year":"2015","unstructured":"Li N, Yang L, Wang H, Yi T, Jia X, Chen C, et al. MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS ONE. 2015;10:e0128886. https:\/\/doi.org\/10.1371\/journal.pone.0128886.","journal-title":"PLoS ONE"},{"key":"2005_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcdb.2020.08.010","volume":"113","author":"IE Wassing","year":"2021","unstructured":"Wassing IE, Esashi F. RAD51: beyond the break. Semin Cell Dev Biol. 2021;113:38\u201346. https:\/\/doi.org\/10.1016\/j.semcdb.2020.08.010.","journal-title":"Semin Cell Dev Biol"},{"key":"2005_CR83","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s40880-015-0049-z","volume":"34","author":"G Liu","year":"2015","unstructured":"Liu G, Xue F, Zhang W. miR-506: a regulator of chemo-sensitivity through suppression of the RAD51-homologous recombination axis. Chin J Cancer. 2015;34:485\u20137. https:\/\/doi.org\/10.1186\/s40880-015-0049-z.","journal-title":"Chin J Cancer"},{"key":"2005_CR84","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41419-018-0390-7","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, et al. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 2018;9:447. https:\/\/doi.org\/10.1038\/s41419-018-0390-7.","journal-title":"Cell Death Dis"},{"key":"2005_CR85","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13048-017-0321-8","volume":"10","author":"M Xiao","year":"2017","unstructured":"Xiao M, Cai J, Cai L, Jia J, Xie L, Zhu Y, et al. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res. 2017;10:24. https:\/\/doi.org\/10.1186\/s13048-017-0321-8.","journal-title":"J Ovarian Res"},{"key":"2005_CR86","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3892\/or.2014.3640","volume":"33","author":"H Zhao","year":"2015","unstructured":"Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo G, et al. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep. 2015;33:591\u20138. https:\/\/doi.org\/10.3892\/or.2014.3640.","journal-title":"Oncol Rep"},{"key":"2005_CR87","doi-asserted-by":"publisher","first-page":"102651","DOI":"10.1016\/j.dnarep.2019.102651","volume":"81","author":"Y Wang","year":"2019","unstructured":"Wang Y, Luo W, Wang Y. PARP-1 and its associated nucleases in DNA damage response. DNA Repair (Amst). 2019;81:102651. https:\/\/doi.org\/10.1016\/j.dnarep.2019.102651.","journal-title":"DNA Repair (Amst)"},{"key":"2005_CR88","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/cgt.2017.6","volume":"24","author":"Y Liu","year":"2017","unstructured":"Liu Y, Niu Z, Lin X, Tian Y. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther. 2017;24:208\u201314. https:\/\/doi.org\/10.1038\/cgt.2017.6.","journal-title":"Cancer Gene Ther"},{"key":"2005_CR89","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41419-018-1148-y","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Fang L, Jiang J, Kuang Y, Wang B, Shang X, et al. The cisplatin-induced LncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018;9:1103. https:\/\/doi.org\/10.1038\/s41419-018-1148-y.","journal-title":"Cell Death Dis"},{"key":"2005_CR90","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e13","author":"H Wang","year":"2023","unstructured":"Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S, et al. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4\/SIRT6 axis. J Gynecol Oncol. 2023. https:\/\/doi.org\/10.3802\/jgo.2024.35.e13.","journal-title":"J Gynecol Oncol"},{"key":"2005_CR91","doi-asserted-by":"publisher","unstructured":"Z C, W M, S C, S F, P C. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2\/Caspase-3 signaling pathway. Biosci Trends. 2018;12. https:\/\/doi.org\/10.5582\/bst.2018.01052.","DOI":"10.5582\/bst.2018.01052"},{"key":"2005_CR92","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1002\/1878-0261.13045","volume":"15","author":"A Wambecke","year":"2021","unstructured":"Wambecke A, Ahmad M, Morice P-M, Lambert B, Weiswald L-B, Vernon M, et al. The LncRNA UCA1 modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels. Mol Oncol. 2021;15:3659\u201378. https:\/\/doi.org\/10.1002\/1878-0261.13045.","journal-title":"Mol Oncol"},{"key":"2005_CR93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtn.2019.05.007","volume":"17","author":"Z Li","year":"2019","unstructured":"Li Z, Niu H, Qin Q, Yang S, Wang Q, Yu C, et al. LncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143\/FOSL2-Signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 2019;17:92\u2013101. https:\/\/doi.org\/10.1016\/j.omtn.2019.05.007.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2005_CR94","doi-asserted-by":"publisher","first-page":"798","DOI":"10.4143\/crt.2019.498","volume":"52","author":"D-Y Wang","year":"2020","unstructured":"Wang D-Y, Li N, Cui Y-L. Long Non-coding RNA CCAT1 sponges miR-454 to promote chemoresistance of ovarian cancer cells to cisplatin by regulation of surviving. Cancer Res Treat. 2020;52:798\u2013814. https:\/\/doi.org\/10.4143\/crt.2019.498.","journal-title":"Cancer Res Treat"},{"key":"2005_CR95","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.3390\/ijms23147737","volume":"23","author":"R Noriega-Rivera","year":"2022","unstructured":"Noriega-Rivera R, Rivera-Serrano M, Rabelo-Fernandez RJ, P\u00e9rez-Santiago J, Valiyeva F, Vivas-Mej\u00eda PE. Upregulation of the long noncoding RNA CASC10 promotes cisplatin resistance in High-Grade serous ovarian cancer. Int J Mol Sci. 2022;23:7737. https:\/\/doi.org\/10.3390\/ijms23147737.","journal-title":"Int J Mol Sci"},{"key":"2005_CR96","doi-asserted-by":"publisher","first-page":"26093","DOI":"10.1038\/srep26093","volume":"6","author":"Z-G Zheng","year":"2016","unstructured":"Zheng Z-G, Xu H, Suo S-S, Xu X-L, Ni M-W, Gu L-H, et al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in High-Grade serous ovarian cancer. Sci Rep. 2016;6:26093. https:\/\/doi.org\/10.1038\/srep26093.","journal-title":"Sci Rep"},{"key":"2005_CR97","doi-asserted-by":"publisher","first-page":"643129","DOI":"10.3389\/fonc.2021.643129","volume":"11","author":"F Bi","year":"2021","unstructured":"Bi F, An Y, Sun T, You Y, Yang Q. PHGDH is upregulated at translational level and implicated in Platin-Resistant in ovarian cancer cells. Front Oncol. 2021;11:643129. https:\/\/doi.org\/10.3389\/fonc.2021.643129.","journal-title":"Front Oncol"},{"key":"2005_CR98","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10565-021-09650-9","volume":"38","author":"X Li","year":"2022","unstructured":"Li X, Zhang Y, Wang X, Lin F, Cheng X, Wang Z, et al. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular Glycolysis and regulating c-Myc expression through PKM2. Cell Biol Toxicol. 2022;38:1027\u201345. https:\/\/doi.org\/10.1007\/s10565-021-09650-9.","journal-title":"Cell Biol Toxicol"},{"key":"2005_CR99","doi-asserted-by":"publisher","first-page":"216241","DOI":"10.1016\/j.canlet.2023.216241","volume":"565","author":"Y Shao","year":"2023","unstructured":"Shao Y, Li H, Wu Y, Wang X, Meng J, Hu Z, et al. The feedback loop of AURKA\/DDX5\/TMEM147-AS1\/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer. Cancer Lett. 2023;565:216241. https:\/\/doi.org\/10.1016\/j.canlet.2023.216241.","journal-title":"Cancer Lett"},{"key":"2005_CR100","doi-asserted-by":"publisher","first-page":"14768","DOI":"10.1038\/s41598-020-71153-0","volume":"10","author":"W-X Tan","year":"2020","unstructured":"Tan W-X, Sun G, Shangguan M-Y, Gui Z, Bao Y, Li Y-F, et al. Novel role of LncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling. Sci Rep. 2020;10:14768. https:\/\/doi.org\/10.1038\/s41598-020-71153-0.","journal-title":"Sci Rep"},{"key":"2005_CR101","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.yexcr.2018.03.014","volume":"366","author":"L Bai","year":"2018","unstructured":"Bai L, Wang A, Zhang Y, Xu X, Zhang X. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 2018;366:161\u201371. https:\/\/doi.org\/10.1016\/j.yexcr.2018.03.014.","journal-title":"Exp Cell Res"},{"key":"2005_CR102","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms22041882","volume":"22","author":"AM Elsayed","year":"2021","unstructured":"Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, et al. PRKAR1B-AS2 long noncoding RNA promotes Tumorigenesis, Survival, and chemoresistance via the PI3K\/AKT\/mTOR pathway. Int J Mol Sci. 2021;22:1882. https:\/\/doi.org\/10.3390\/ijms22041882.","journal-title":"Int J Mol Sci"},{"key":"2005_CR103","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/dna.2021.0059","volume":"40","author":"H Yang","year":"2021","unstructured":"Yang H, Zhang X, Zhu L, Yang Y, Yin X. YY1-Induced LncRNA PART1 enhanced resistance of ovarian cancer cells to cisplatin by regulating miR-512-3p\/CHRAC1 axis. DNA Cell Biol. 2021;40:821\u201332. https:\/\/doi.org\/10.1089\/dna.2021.0059.","journal-title":"DNA Cell Biol"},{"key":"2005_CR104","doi-asserted-by":"publisher","first-page":"153957","DOI":"10.1016\/j.prp.2022.153957","volume":"235","author":"J Wu","year":"2022","unstructured":"Wu J, Ni X, Yu Z, Wu S, Liu Z. CRNDE inducing cisplatin resistance through SRSF1\/TIA1 signaling pathway in ovarian cancer. Pathol Res Pract. 2022;235:153957. https:\/\/doi.org\/10.1016\/j.prp.2022.153957.","journal-title":"Pathol Res Pract"},{"key":"2005_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-06084-5","volume":"14","author":"L Ren","year":"2023","unstructured":"Ren L, Qing X, Wei J, Mo H, Liu Y, Zhi Y, et al. The DDUP protein encoded by the DNA damage-induced CTBP1-DT LncRNA confers cisplatin resistance in ovarian cancer. Cell Death Dis. 2023;14:1\u201315. https:\/\/doi.org\/10.1038\/s41419-023-06084-5.","journal-title":"Cell Death Dis"},{"key":"2005_CR106","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-019-1329-2","volume":"38","author":"X Long","year":"2019","unstructured":"Long X, Song K, Hu H, Tian Q, Wang W, Dong Q, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res. 2019;38:345. https:\/\/doi.org\/10.1186\/s13046-019-1329-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"2005_CR107","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13048-023-01247-6","volume":"16","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang X, Zheng F, Yang Q, Bi F. Mitophagy-related long non-coding RNA signature predicts prognosis and drug response in ovarian cancer. J Ovarian Res. 2023;16:177. https:\/\/doi.org\/10.1186\/s13048-023-01247-6.","journal-title":"J Ovarian Res"},{"key":"2005_CR108","doi-asserted-by":"publisher","unstructured":"DongY-J, Feng W, Li Y. HOTTIP-miR-205-ZEB2 axis confers cisplatin resistance to ovarian cancer cells. Front Cell Dev Biology. 2021;9. https:\/\/doi.org\/10.3389\/fcell.2021.707424.","DOI":"10.3389\/fcell.2021.707424"},{"key":"2005_CR109","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12935-023-03029-y","volume":"23","author":"Y Wu","year":"2023","unstructured":"Wu Y, Wang T, Xia L, Zhang M. Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p\/SDC4 axis. Cancer Cell Int. 2023;23:176. https:\/\/doi.org\/10.1186\/s12935-023-03029-y.","journal-title":"Cancer Cell Int"},{"key":"2005_CR110","doi-asserted-by":"publisher","first-page":"709324","DOI":"10.3389\/fphar.2021.709324","volume":"12","author":"Q Mu","year":"2021","unstructured":"Mu Q, Lv Y, Luo C, Liu X, Huang C, Xiu Y, et al. Research progress on the functions and mechanism of circrna in cisplatin resistance in tumors. Front Pharmacol. 2021;12:709324. https:\/\/doi.org\/10.3389\/fphar.2021.709324.","journal-title":"Front Pharmacol"},{"key":"2005_CR111","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ncrna.2024.05.005","volume":"9","author":"M Malek Mohammadi","year":"2024","unstructured":"Malek Mohammadi M, Rismanchi H, Esmailzadeh S, Farahani A, Hedayati N, Alimohammadi M, et al. The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: from molecular mechanism to future potential. Non-Coding RNA Res. 2024;9:1280\u201391. https:\/\/doi.org\/10.1016\/j.ncrna.2024.05.005.","journal-title":"Non-Coding RNA Res"},{"key":"2005_CR112","doi-asserted-by":"publisher","first-page":"e004029","DOI":"10.1136\/jitc-2021-004029","volume":"10","author":"H Li","year":"2022","unstructured":"Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, et al. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J Immunother Cancer. 2022;10:e004029. https:\/\/doi.org\/10.1136\/jitc-2021-004029.","journal-title":"J Immunother Cancer"},{"key":"2005_CR113","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12951-024-02295-w","volume":"22","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Liang L, Zhao Y, Li J, Zeng J, Yuan Y, et al. CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination. J Nanobiotechnol. 2024;22:35. https:\/\/doi.org\/10.1186\/s12951-024-02295-w.","journal-title":"J Nanobiotechnol"},{"key":"2005_CR114","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/15384047.2021.1959792","volume":"22","author":"J Yin","year":"2021","unstructured":"Yin J, Huang H-Y, Long Y, Ma Y, Kamalibaike M, Dawuti R, et al. circ_C20orf11 enhances DDP resistance by inhibiting miR-527\/YWHAZ through the promotion of extracellular vesicle-mediated macrophage M2 polarization in ovarian cancer. Cancer Biol Ther. 2021;22:440\u201354. https:\/\/doi.org\/10.1080\/15384047.2021.1959792.","journal-title":"Cancer Biol Ther"},{"key":"2005_CR115","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.3802\/jgo.2020.31.e75","volume":"31","author":"Y Luo","year":"2020","unstructured":"Luo Y, Gui R. Circulating Exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells. J Gynecol Oncol. 2020;31:e75. https:\/\/doi.org\/10.3802\/jgo.2020.31.e75.","journal-title":"J Gynecol Oncol"},{"key":"2005_CR116","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.5114\/aoms\/133038","volume":"20","author":"H Yao","year":"2024","unstructured":"Yao H, Liu D, Gao F, Li Q, Liu S. Circ-VPS13C enhances cisplatin resistance in ovarian cancer via modulating the miR-106b-5p\/YWHAZ axis. Arch Med Sci. 2024;20:1249\u201367. https:\/\/doi.org\/10.5114\/aoms\/133038.","journal-title":"Arch Med Sci"},{"key":"2005_CR117","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2023.11.034","volume":"180","author":"X Yin","year":"2023","unstructured":"Yin X, Zhao S, Zhang M, Xing J, Zhou J, Gao W, et al. m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer. Gynecol Oncol. 2023;180:99\u2013110. https:\/\/doi.org\/10.1016\/j.ygyno.2023.11.034.","journal-title":"Gynecol Oncol"},{"key":"2005_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6811","author":"Y Fan","year":"2023","unstructured":"Fan Y, Pan Y, Jia L, Gu S, Liu B, Mei Z, et al. BIRC5 facilitates cisplatin-chemoresistance in a m6 A-dependent manner in ovarian cancer. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.6811.","journal-title":"Cancer Med"},{"key":"2005_CR119","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s10495-025-02094-0","volume":"30","author":"J Miao","year":"2025","unstructured":"Miao J, Jiang X, Wang S. YTHDF1-mediated m6A modification promotes cisplatin resistance in ovarian cancer via the FZD7\/Wnt\/\u03b2-catenin pathway. Apoptosis. 2025;30:1525\u201346. https:\/\/doi.org\/10.1007\/s10495-025-02094-0.","journal-title":"Apoptosis"},{"key":"2005_CR120","doi-asserted-by":"publisher","first-page":"115484","DOI":"10.1016\/j.celrep.2025.115484","volume":"44","author":"Q Xia","year":"2025","unstructured":"Xia Q, Zhong R, Zheng J, Zhou X, Zhao X, Wang S, et al. PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms. Cell Rep. 2025;44:115484. https:\/\/doi.org\/10.1016\/j.celrep.2025.115484.","journal-title":"Cell Rep"},{"key":"2005_CR121","doi-asserted-by":"publisher","first-page":"215971","DOI":"10.1016\/j.canlet.2022.215971","volume":"553","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qiu J-G, Jia X-Y, Ke Y, Zhang M-K, Stieg D, et al. METTL3-mediated N6-methyladenosine modification and HDAC5\/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance. Cancer Lett. 2023;553:215971. https:\/\/doi.org\/10.1016\/j.canlet.2022.215971.","journal-title":"Cancer Lett"},{"key":"2005_CR122","doi-asserted-by":"publisher","first-page":"e24761","DOI":"10.1002\/jcla.24761","volume":"36","author":"S Cui","year":"2022","unstructured":"Cui S. METTL3-mediated m6A modification of Lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K\/AKT pathway. J Clin Lab Anal. 2022;36:e24761. https:\/\/doi.org\/10.1002\/jcla.24761.","journal-title":"J Clin Lab Anal"},{"key":"2005_CR123","doi-asserted-by":"publisher","first-page":"118878","DOI":"10.1016\/j.bbamcr.2020.118878","volume":"1868","author":"L Hao","year":"2021","unstructured":"Hao L, Wang J-M, Liu B-Q, Yan J, Li C, Jiang J-Y, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868:118878. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118878.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2005_CR124","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-021-02088-1","volume":"40","author":"S Nie","year":"2021","unstructured":"Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021;40:284. https:\/\/doi.org\/10.1186\/s13046-021-02088-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"19990601","key":"2005_CR125","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/(sici)1097-0142","volume":"85","author":"T Kamura","year":"1999","unstructured":"Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous. adenocarcinoma? Cancer. 1999;85(19990601):2450\u20134. https:\/\/doi.org\/10.1002\/(sici)1097-0142. )85:11%253C2450::aid-cncr21%253E3.0.co;2-u.","journal-title":"adenocarcinoma? Cancer"},{"key":"2005_CR126","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1093\/nar\/gkx711","volume":"45","author":"H Hoffmeister","year":"2017","unstructured":"Hoffmeister H, Fuchs A, Erdel F, Pinz S, Gr\u00f6bner-Ferreira R, Bruckmann A, et al. CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. Nucleic Acids Res. 2017;45:10534\u201354. https:\/\/doi.org\/10.1093\/nar\/gkx711.","journal-title":"Nucleic Acids Res"},{"key":"2005_CR127","doi-asserted-by":"publisher","first-page":"217064","DOI":"10.1016\/j.canlet.2024.217064","volume":"597","author":"H Meng","year":"2024","unstructured":"Meng H, Miao H, Zhang Y, Chen T, Yuan L, Wan Y, et al. YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification. Cancer Lett. 2024;597:217064. https:\/\/doi.org\/10.1016\/j.canlet.2024.217064.","journal-title":"Cancer Lett"},{"key":"2005_CR128","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13048-025-01753-9","volume":"18","author":"K Zhang","year":"2025","unstructured":"Zhang K, Cheng G, Jiang W, Kong B, Yao S, Liu X. 5-methylcytosine regulated CCNL2 promotes tumorigenesis and cisplatin resistance of ovarian cancer with therapeutic implications. J Ovarian Res. 2025;18:162. https:\/\/doi.org\/10.1186\/s13048-025-01753-9.","journal-title":"J Ovarian Res"},{"key":"2005_CR129","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-023-01917-5","volume":"23","author":"H Li","year":"2024","unstructured":"Li H, Lin R, Zhang Y, Zhu Y, Huang S, Lan J, et al. N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation. Mol Cancer. 2024;23:5. https:\/\/doi.org\/10.1186\/s12943-023-01917-5.","journal-title":"Mol Cancer"},{"key":"2005_CR130","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4161\/cbt.10.8.12913","volume":"10","author":"S Hu","year":"2010","unstructured":"Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 2010;10:788\u201395. https:\/\/doi.org\/10.4161\/cbt.10.8.12913.","journal-title":"Cancer Biol Ther"},{"key":"2005_CR131","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40659-020-00286-3","volume":"53","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Ai H, Fan X, Chen S, Wang Y, Liu L. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. Biol Res. 2020;53:18. https:\/\/doi.org\/10.1186\/s40659-020-00286-3.","journal-title":"Biol Res"},{"key":"2005_CR132","doi-asserted-by":"publisher","first-page":"dev204384","DOI":"10.1242\/dev.204384","volume":"152","author":"Y-H Liu","year":"2025","unstructured":"Liu Y-H, Schneider R. Histone modifications in development. Development. 2025;152:dev204384. https:\/\/doi.org\/10.1242\/dev.204384.","journal-title":"Development"},{"key":"2005_CR133","doi-asserted-by":"publisher","first-page":"567","DOI":"10.16288\/j.yczz.19-077","volume":"41","author":"JW Zhang","year":"2019","unstructured":"Zhang JW, Xu Q, Li GL. [Epigenetics in the genesis and development of cancers]. Yi Chuan. 2019;41:567\u201381. https:\/\/doi.org\/10.16288\/j.yczz.19-077.","journal-title":"Yi Chuan"},{"key":"2005_CR134","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3802\/jgo.2012.23.3.182","volume":"23","author":"M-G Kim","year":"2012","unstructured":"Kim M-G, Pak JH, Choi WH, Park J-Y, Nam J-H, Kim J-H. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. J Gynecol Oncol. 2012;23:182\u20139. https:\/\/doi.org\/10.3802\/jgo.2012.23.3.182.","journal-title":"J Gynecol Oncol"},{"key":"2005_CR135","doi-asserted-by":"publisher","first-page":"934246","DOI":"10.3389\/fgene.2022.934246","volume":"13","author":"X-Q Hu","year":"2022","unstructured":"Hu X-Q, Zhang X-C, Li S-T, Hua T. Construction and validation of a histone acetylation-related LncRNA prognosis signature for ovarian cancer. Front Genet. 2022;13:934246. https:\/\/doi.org\/10.3389\/fgene.2022.934246.","journal-title":"Front Genet"},{"key":"2005_CR136","doi-asserted-by":"publisher","first-page":"111044","DOI":"10.1016\/j.cellsig.2024.111044","volume":"116","author":"J Huang","year":"2024","unstructured":"Huang J, Tang Y, Li Y, Wei W, Kang F, Tan S, et al. ALDH1A3 contributes to tumorigenesis in high-grade serous ovarian cancer by epigenetic modification. Cell Signal. 2024;116:111044. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111044.","journal-title":"Cell Signal"},{"key":"2005_CR137","doi-asserted-by":"publisher","first-page":"e2015808118","DOI":"10.1073\/pnas.2015808118","volume":"118","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Lin F-T, Lin W-C. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer. Proc Natl Acad Sci U S A. 2021;118:e2015808118. https:\/\/doi.org\/10.1073\/pnas.2015808118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2005_CR138","doi-asserted-by":"publisher","first-page":"8300","DOI":"10.3390\/ijms21218300","volume":"21","author":"AJ Rodrigues Moita","year":"2020","unstructured":"Rodrigues Moita AJ, Bandolik JJ, Hansen FK, Kurz T, Hamacher A, Kassack MU. Priming with HDAC inhibitors sensitizes ovarian cancer cells to treatment with cisplatin and HSP90 inhibitors. Int J Mol Sci. 2020;21:8300. https:\/\/doi.org\/10.3390\/ijms21218300.","journal-title":"Int J Mol Sci"},{"key":"2005_CR139","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ygyno.2020.07.005","volume":"159","author":"E Taylan","year":"2020","unstructured":"Taylan E, Zayou F, Murali R, Karlan BY, Pandol SJ, Edderkaoui M, et al. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. Gynecol Oncol. 2020;159:277\u201384. https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.005.","journal-title":"Gynecol Oncol"},{"key":"2005_CR140","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41467-018-03590-5","volume":"9","author":"D Liu","year":"2018","unstructured":"Liu D, Zhang X-X, Li M-C, Cao C-H, Wan D-Y, Xi B-X, et al. C\/EBP\u03b2 enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9:1739. https:\/\/doi.org\/10.1038\/s41467-018-03590-5.","journal-title":"Nat Commun"},{"key":"2005_CR141","doi-asserted-by":"publisher","first-page":"103558","DOI":"10.1016\/j.ebiom.2021.103558","volume":"71","author":"G Wu","year":"2021","unstructured":"Wu G, Peng H, Tang M, Yang M, Wang J, Hu Y, et al. ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine. 2021;71:103558. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103558.","journal-title":"EBioMedicine"},{"key":"2005_CR142","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/onc.2016.320","volume":"36","author":"S Ramadoss","year":"2017","unstructured":"Ramadoss S, Sen S, Ramachandran I, Roy S, Chaudhuri G, Farias-Eisner R. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene. 2017;36:1537\u201345. https:\/\/doi.org\/10.1038\/onc.2016.320.","journal-title":"Oncogene"},{"key":"2005_CR143","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ygyno.2011.10.013","volume":"124","author":"C Yang","year":"2012","unstructured":"Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L, et al. Epigenetic Silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 2012;124:325\u201334. https:\/\/doi.org\/10.1016\/j.ygyno.2011.10.013.","journal-title":"Gynecol Oncol"},{"key":"2005_CR144","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/cbin.11486","volume":"45","author":"X Han","year":"2021","unstructured":"Han X, Liu D, Zhou Y, Wang L, Hou H, Chen H, et al. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer. Cell Biol Int. 2021;45:227\u201337. https:\/\/doi.org\/10.1002\/cbin.11486.","journal-title":"Cell Biol Int"},{"key":"2005_CR145","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3892\/ol.2018.9745","volume":"17","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang X, Huang Y, Zhang Q, Zhou J, Zhang X, et al. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol Lett. 2019;17:1453\u201360. https:\/\/doi.org\/10.3892\/ol.2018.9745.","journal-title":"Oncol Lett"},{"key":"2005_CR146","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13048-017-0333-4","volume":"10","author":"Y Deng","year":"2017","unstructured":"Deng Y, Zhao F, Hui L, Li X, Zhang D, Lin W, et al. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. J Ovarian Res. 2017;10:50. https:\/\/doi.org\/10.1186\/s13048-017-0333-4.","journal-title":"J Ovarian Res"},{"key":"2005_CR147","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/onc.2012.575","volume":"33","author":"Y Xiang","year":"2014","unstructured":"Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014;33:378\u201386. https:\/\/doi.org\/10.1038\/onc.2012.575.","journal-title":"Oncogene"},{"key":"2005_CR148","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41598-017-00966-3","volume":"7","author":"AR \u00d6ze\u015f","year":"2017","unstructured":"\u00d6ze\u015f AR, Wang Y, Zong X, Fang F, Pilrose J, Nephew KP. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017;7:894. https:\/\/doi.org\/10.1038\/s41598-017-00966-3.","journal-title":"Sci Rep"},{"key":"2005_CR149","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Fran\u00e7a","year":"2024","unstructured":"Fran\u00e7a GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature. 2024;631:876\u201383. https:\/\/doi.org\/10.1038\/s41586-024-07690-9.","journal-title":"Nature"},{"key":"2005_CR150","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pneurobio.2016.06.005","volume":"143","author":"SL Hollins","year":"2016","unstructured":"Hollins SL, Cairns MJ. MicroRNA: small RNA mediators of the brains genomic response to environmental stress. Prog Neurobiol. 2016;143:61\u201381. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.06.005.","journal-title":"Prog Neurobiol"},{"key":"2005_CR151","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00018-010-0505-5","volume":"68","author":"VA Blomen","year":"2011","unstructured":"Blomen VA, Boonstra J. Stable transmission of reversible modifications: maintenance of epigenetic information through the cell cycle. Cell Mol Life Sci. 2011;68:27\u201344. https:\/\/doi.org\/10.1007\/s00018-010-0505-5.","journal-title":"Cell Mol Life Sci"},{"key":"2005_CR152","doi-asserted-by":"publisher","first-page":"100993","DOI":"10.1016\/j.drup.2023.100993","volume":"71","author":"D Ravindran Menon","year":"2023","unstructured":"Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, et al. H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resist Updat. 2023;71:100993. https:\/\/doi.org\/10.1016\/j.drup.2023.100993.","journal-title":"Drug Resist Updat"},{"key":"2005_CR153","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5483\/BMBRep.2022-0202","volume":"56","author":"HY Sung","year":"2023","unstructured":"Sung HY, Han J, Chae YJ, Ju W, Lee Kang J, Park AK, et al. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance. BMB Rep. 2023;56:347\u201352. https:\/\/doi.org\/10.5483\/BMBRep.2022-0202.","journal-title":"BMB Rep"},{"key":"2005_CR154","doi-asserted-by":"publisher","first-page":"e34978","DOI":"10.1016\/j.heliyon.2024.e34978","volume":"10","author":"J Wang","year":"2024","unstructured":"Wang J, Wu Y. MicroRNA-486-3p affects cisplatin resistance in high-grade serous ovarian cancer by regulating TMIGD2: an experimental study. Heliyon. 2024;10:e34978. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34978.","journal-title":"Heliyon"},{"key":"2005_CR155","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41419-025-07430-5","volume":"16","author":"D Shukla","year":"2025","unstructured":"Shukla D, Mishra S, Mandal T, Charan M, Verma AK, Khan MMA, et al. MicroRNA-379-5p attenuates cancer stem cells and reduces cisplatin resistance in ovarian cancer by regulating RAD18\/Pol\u03b7 axis. Cell Death Dis. 2025;16:140. https:\/\/doi.org\/10.1038\/s41419-025-07430-5.","journal-title":"Cell Death Dis"},{"key":"2005_CR156","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.28399","volume":"134","author":"P-N Yu","year":"2014","unstructured":"Yu P-N, Yan M-D, Lai H-C, Huang R-L, Chou Y-C, Lin W-C, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014;134:542\u201351. https:\/\/doi.org\/10.1002\/ijc.28399.","journal-title":"Int J Cancer"},{"key":"2005_CR157","doi-asserted-by":"publisher","first-page":"814291","DOI":"10.3389\/fgene.2022.814291","volume":"13","author":"T Liu","year":"2022","unstructured":"Liu T, Shen J, He Q, Xu S. Identification of a novel Immune-Related LncRNA CTD-2288O8.1 regulating cisplatin resistance in ovarian cancer based on integrated analysis. Front Genet. 2022;13:814291. https:\/\/doi.org\/10.3389\/fgene.2022.814291.","journal-title":"Front Genet"},{"key":"2005_CR158","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1016\/j.ygeno.2020.08.005","volume":"112","author":"N El-Khazragy","year":"2020","unstructured":"El-Khazragy N, Mohammed HF, Yassin M, Elghoneimy KK, Bayoumy W, Hewety A, et al. Tissue-based long non-coding RNAs PVT1, TUG1 and MEG3 signature predicts cisplatin resistance in ovarian cancer. Genomics. 2020;112:4640\u20136. https:\/\/doi.org\/10.1016\/j.ygeno.2020.08.005.","journal-title":"Genomics"},{"key":"2005_CR159","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12935-021-02076-7","volume":"21","author":"J Zheng","year":"2021","unstructured":"Zheng J, Guo J, Cao B, Zhou Y, Tong J. Identification and validation of LncRNAs involved in m6A regulation for patients with ovarian cancer. Cancer Cell Int. 2021;21:363. https:\/\/doi.org\/10.1186\/s12935-021-02076-7.","journal-title":"Cancer Cell Int"},{"key":"2005_CR160","doi-asserted-by":"publisher","first-page":"e70244","DOI":"10.1002\/ctm2.70244","volume":"15","author":"Y Wu","year":"2025","unstructured":"Wu Y, Zeng Y, Wu Y, Ha X, Feng Z, Liu C, et al. HIF-1\u03b1-induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP-ribosylation. Clin Transl Med. 2025;15:e70244. https:\/\/doi.org\/10.1002\/ctm2.70244.","journal-title":"Clin Transl Med"},{"key":"2005_CR161","doi-asserted-by":"publisher","first-page":"e87455","DOI":"10.1371\/journal.pone.0087455","volume":"9","author":"E Cacan","year":"2014","unstructured":"Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS ONE. 2014;9:e87455. https:\/\/doi.org\/10.1371\/journal.pone.0087455.","journal-title":"PLoS ONE"},{"key":"2005_CR162","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41420-025-02618-2","volume":"11","author":"I Singh","year":"2025","unstructured":"Singh I, Karna A, Prajapati A, Solanki U, Mukherjee A, Uppal S, et al. Epigenetic targeting of MECOM\/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer. Cell Death Discov. 2025;11:326. https:\/\/doi.org\/10.1038\/s41420-025-02618-2.","journal-title":"Cell Death Discov"},{"key":"2005_CR163","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.3390\/cancers14194761","volume":"14","author":"I Samar\u017eija","year":"2022","unstructured":"Samar\u017eija I, Tomljanovi\u0107 M, Novak Kujund\u017ei\u0107 R, Tro\u0161elj KG. EZH2 Inhibition and cisplatin as a combination anticancer therapy: an overview of preclinical studies. Cancers (Basel). 2022;14:4761. https:\/\/doi.org\/10.3390\/cancers14194761.","journal-title":"Cancers (Basel)"},{"key":"2005_CR164","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-19-0215","volume":"79","author":"S Shang","year":"2019","unstructured":"Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, et al. Chemotherapy-Induced distal enhancers drive transcriptional programs to maintain the chemoresistant state in ovarian cancer. Cancer Res. 2019;79:4599\u2013611. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0215.","journal-title":"Cancer Res"},{"key":"2005_CR165","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13402-020-00578-6","volume":"44","author":"A Andrikopoulou","year":"2021","unstructured":"Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos M-A, Zagouri F. Clinical perspectives of BET Inhibition in ovarian cancer. Cell Oncol (Dordr). 2021;44:237\u201349. https:\/\/doi.org\/10.1007\/s13402-020-00578-6.","journal-title":"Cell Oncol (Dordr)"},{"key":"2005_CR166","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-16-0854","volume":"76","author":"Y Yokoyama","year":"2016","unstructured":"Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, et al. BET inhibitors suppress ALDH activity by targeting ALDH1A1 Super-Enhancer in ovarian cancer. Cancer Res. 2016;76:6320\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0854.","journal-title":"Cancer Res"},{"key":"2005_CR167","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/cncr.25701","volume":"117","author":"S Fu","year":"2011","unstructured":"Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011;117:1661\u20139. https:\/\/doi.org\/10.1002\/cncr.25701.","journal-title":"Cancer"},{"key":"2005_CR168","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","volume":"72","author":"D Matei","year":"2012","unstructured":"Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012;72:2197\u2013205. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3909.","journal-title":"Cancer Res"},{"key":"2005_CR169","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/biom7010003","volume":"7","author":"O Castillo-Aguilera","year":"2017","unstructured":"Castillo-Aguilera O, Depreux P, Halby L, Arimondo PB, Goossens L. DNA methylation targeting: the DNMT\/HMT crosstalk challenge. Biomolecules. 2017;7:3. https:\/\/doi.org\/10.3390\/biom7010003.","journal-title":"Biomolecules"},{"key":"2005_CR170","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s10637-013-0003-3","volume":"31","author":"GS Falchook","year":"2013","unstructured":"Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, et al. Methylation and histone deacetylase Inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013;31:1192\u2013200. https:\/\/doi.org\/10.1007\/s10637-013-0003-3.","journal-title":"Invest New Drugs"},{"key":"2005_CR171","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630\u201341. https:\/\/doi.org\/10.1038\/nrg.2016.93.","journal-title":"Nat Rev Genet"},{"key":"2005_CR172","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","volume":"11","author":"S Moufarrij","year":"2019","unstructured":"Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11:7. https:\/\/doi.org\/10.1186\/s13148-018-0602-0.","journal-title":"Clin Epigenetics"},{"key":"2005_CR173","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","volume":"2","author":"K Odunsi","year":"2014","unstructured":"Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014;2:37\u201349. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0126.","journal-title":"Cancer Immunol Res"},{"key":"2005_CR174","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-19-1638","volume":"26","author":"AM Oza","year":"2020","unstructured":"Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, et al. A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in Platinum-resistant, recurrent ovarian cancer. Clin Cancer Res. 2020;26:1009\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1638.","journal-title":"Clin Cancer Res"},{"key":"2005_CR175","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2326-6066.CIR-15-0073","volume":"3","author":"L Wang","year":"2015","unstructured":"Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 Blockade in a murine ovarian cancer model. Cancer Immunol Res. 2015;3:1030\u201341. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0073.","journal-title":"Cancer Immunol Res"},{"key":"2005_CR176","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345. https:\/\/doi.org\/10.1200\/JCO.2012.42.0505.","journal-title":"J Clin Oncol"},{"key":"2005_CR177","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23:66. https:\/\/doi.org\/10.1186\/s12943-024-01967-3.","journal-title":"Mol Cancer"},{"key":"2005_CR178","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2368","author":"Y Wang","year":"2024","unstructured":"Wang Y, Situ X, Cardenas H, Siu E, Alhunayan RA, Keathley R, et al. Preclinical evaluation of NTX-301, a novel DNA hypomethylating agent in ovarian cancer. Clin Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2368.","journal-title":"Clin Cancer Res"},{"key":"2005_CR179","doi-asserted-by":"publisher","first-page":"10817","DOI":"10.3390\/ijms241310817","volume":"24","author":"Y Nakagawa-Saito","year":"2023","unstructured":"Nakagawa-Saito Y, Mitobe Y, Suzuki S, Togashi K, Sugai A, Kitanaka C, et al. Domatinostat targets the FOXM1-Survivin axis to reduce the viability of ovarian cancer cells alone and in combination with chemotherapeutic agents. Int J Mol Sci. 2023;24:10817. https:\/\/doi.org\/10.3390\/ijms241310817.","journal-title":"Int J Mol Sci"},{"key":"2005_CR180","doi-asserted-by":"publisher","first-page":"11260","DOI":"10.1021\/acs.jmedchem.9b01489","volume":"62","author":"V Krieger","year":"2019","unstructured":"Krieger V, Hamacher A, Cao F, Stenzel K, Gertzen CGW, Sch\u00e4ker-H\u00fcbner L, et al. Synthesis of Peptoid-Based class I-Selective histone deacetylase inhibitors with chemosensitizing properties. J Med Chem. 2019;62:11260\u201379. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01489.","journal-title":"J Med Chem"},{"key":"2005_CR181","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/cam4.5012","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yang X, Zhuang Z, Wei M, Meng W, Deng X, et al. The diagnostic value of Exosomal circular RNAs in cancer patients: A systematic review and meta-analysis. Cancer Med. 2023;12:1709\u201320. https:\/\/doi.org\/10.1002\/cam4.5012.","journal-title":"Cancer Med"},{"key":"2005_CR182","doi-asserted-by":"publisher","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updates. 2023;68:100938. https:\/\/doi.org\/10.1016\/j.drup.2023.100938.","journal-title":"Drug Resist Updates"},{"key":"2005_CR183","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13062-023-00360-2","volume":"18","author":"A Smirnov","year":"2023","unstructured":"Smirnov A, Melino G, Candi E. Gene expression in organoids: an expanding horizon. Biol Direct. 2023;18:11. https:\/\/doi.org\/10.1186\/s13062-023-00360-2.","journal-title":"Biol Direct"},{"key":"2005_CR184","doi-asserted-by":"publisher","first-page":"101736","DOI":"10.1016\/j.xcrm.2024.101736","volume":"5","author":"A Tivey","year":"2024","unstructured":"Tivey A, Lee RJ, Clipson A, Hill SM, Lorigan P, Rothwell DG, et al. Mining nucleic acid omics to boost liquid biopsy in cancer. Cell Rep Med. 2024;5:101736. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101736.","journal-title":"Cell Rep Med"},{"key":"2005_CR185","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13073-024-01407-3","volume":"16","author":"K Fang","year":"2024","unstructured":"Fang K, Ohihoin AG, Liu T, Choppavarapu L, Nosirov B, Wang Q, et al. Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell States and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer. Genome Med. 2024;16:134. https:\/\/doi.org\/10.1186\/s13073-024-01407-3.","journal-title":"Genome Med"},{"key":"2005_CR186","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","volume":"164","author":"M Tkach","year":"2016","unstructured":"Tkach M, Th\u00e9ry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226\u201332. https:\/\/doi.org\/10.1016\/j.cell.2016.01.043.","journal-title":"Cell"},{"key":"2005_CR187","doi-asserted-by":"publisher","first-page":"28585","DOI":"10.1021\/acsami.5c03827","volume":"17","author":"C Wang","year":"2025","unstructured":"Wang C, Wang Z, Gao M, Zhu Y, Zhu H, Zhou L, et al. Highly stable and integrable Graphene\/Molybdenum disulfide heterojunction Field-Effect Transistor-Based MiRNA biosensor. ACS Appl Mater Interfaces. 2025;17:28585\u201396. https:\/\/doi.org\/10.1021\/acsami.5c03827.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2005_CR188","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1007\/s00203-021-02357-9","volume":"203","author":"Y Gupta","year":"2021","unstructured":"Gupta Y, Ghrera AS. Recent advances in gold nanoparticle-based lateral flow immunoassay for the detection of bacterial infection. Arch Microbiol. 2021;203:3767\u201384. https:\/\/doi.org\/10.1007\/s00203-021-02357-9.","journal-title":"Arch Microbiol"},{"key":"2005_CR189","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nmeth.4184","volume":"14","author":"JT Simpson","year":"2017","unstructured":"Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting DNA cytosine methylation using nanopore sequencing. Nat Methods. 2017;14:407\u201310. https:\/\/doi.org\/10.1038\/nmeth.4184.","journal-title":"Nat Methods"},{"key":"2005_CR190","doi-asserted-by":"publisher","first-page":"154571","DOI":"10.1016\/j.phymed.2022.154571","volume":"109","author":"G Wang","year":"2023","unstructured":"Wang G, Li L, Li Y, Zhang L-H. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195\/ERK\/\u03b2-catenin pathway. Phytomedicine. 2023;109:154571. https:\/\/doi.org\/10.1016\/j.phymed.2022.154571.","journal-title":"Phytomedicine"},{"key":"2005_CR191","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2147\/DDDT.S288707","volume":"15","author":"S Sarwar","year":"2021","unstructured":"Sarwar S, Alamro AA, Alghamdi AA, Naeem K, Ullah S, Arif M, et al. Enhanced accumulation of cisplatin in ovarian cancer cells from combination with Wedelolactone and resulting Inhibition of multiple epigenetic drivers. Drug Des Devel Ther. 2021;15:2211\u201327. https:\/\/doi.org\/10.2147\/DDDT.S288707.","journal-title":"Drug Des Devel Ther"},{"key":"2005_CR192","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20:50. https:\/\/doi.org\/10.1186\/s12951-022-01264-5.","journal-title":"J Nanobiotechnol"},{"key":"2005_CR193","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.trsl.2018.06.003","volume":"204","author":"TR McCaw","year":"2019","unstructured":"McCaw TR, Randall TD, Arend RC. Overcoming immune suppression with epigenetic modification in ovarian cancer. Transl Res. 2019;204:31\u20138. https:\/\/doi.org\/10.1016\/j.trsl.2018.06.003.","journal-title":"Transl Res"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02005-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T13:05:35Z","timestamp":1775221535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02005-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":193,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02005-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}